How to Value an IV Therapy or Wellness Infusion Business

IV therapy and wellness infusion businesses — vitamin drips, NAD+ infusions, hydration therapy, glutathione pushes — have gone from a niche celebrity wellness trend to a legitimate small business category in under a decade. The IV therapy market has grown to an estimated $3+ billion nationally, and I'm starting to see these businesses show up in acquisition pipelines with increasing frequency. But valuing them requires understanding what's real, what's hype, and what the regulatory risk actually looks like.

I've evaluated a number of these businesses over the past two years, and the range in quality is enormous. Some are well-run clinical operations with recurring membership revenue and proper medical oversight. Others are essentially pop-up retail operations with a nurse and an Instagram account. The valuation difference between those two models is significant.

The Baseline: 2-4x SDE for Single Locations

Single-location IV therapy businesses typically trade at 2.0-4.0x SDE, which places them in line with other owner-operated wellness businesses like med spas and boutique fitness studios. The wide range reflects the enormous variation in business quality within the category.

At the low end (2.0-2.5x SDE), you're looking at businesses with inconsistent revenue, no membership model, heavy owner involvement, and limited brand equity. These are often owner-operated by a nurse practitioner who handles everything from IV insertions to marketing to inventory management. The buyer is essentially purchasing a job, and the price reflects that.

At the high end (3.5-4.0x SDE), you're looking at businesses with strong membership revenue (30%+ of total), a team of nurses who can operate without the owner present, a recognized local brand, and demonstrated growth trajectory. These businesses have built something that can transfer to a new owner, and buyers will pay for that transferability.

Unit Economics: Treatments Per Day and Revenue Per Treatment

The fundamental unit economics of an IV therapy business are straightforward, and they're the first thing I look at in any valuation. A typical IV vitamin infusion takes 30-60 minutes and is priced at $150-$300 depending on the formulation and market. NAD+ infusions, which take 2-4 hours, command $500-$1,000 per treatment. Hydration-only IVs (the hangover/recovery market) are the low end at $99-$175.

The cost of goods is relatively low. IV supplies (bags, tubing, catheters, vitamins) run $15-$40 per treatment depending on the formulation. That creates gross margins of 80-90% on materials, which sounds extraordinary until you factor in labor. A registered nurse administering IVs costs $35-$55 per hour depending on market. If that nurse can handle 3-4 concurrent patients in a well-designed infusion suite, the labor economics work. If she's doing one patient at a time in a single-chair setup, margins compress significantly.

A healthy single-location IV therapy business should be doing 15-25 treatments per day at a blended average of $175-$225 per treatment, generating $800K-$1.5M in annual revenue. Below 10 treatments per day, the business struggles to cover fixed costs (rent, medical director fees, insurance, marketing). Above 25 per day at a single location, you're pushing capacity and likely need to expand.

Membership and Package Revenue: The Multiple Multiplier

The single biggest valuation lever for an IV therapy business is recurring membership revenue. A business where 35-50% of revenue comes from monthly memberships ($199-$399/month for 2-4 infusions) is a fundamentally different asset than one relying on walk-in transactions.

Membership revenue is predictable, reduces customer acquisition costs (members don't need to be remarketed every visit), and demonstrates customer commitment. A business with 200 active members paying $250/month has $600K in annualized recurring revenue before a single walk-in customer arrives. That predictability is what moves the SDE multiple from 2x to 3.5x+.

Package sales (buy 5 get 1 free, prepaid treatment bundles) serve a similar function. While not as sticky as memberships, prepaid packages create deferred revenue that smooths cash flow and indicates customer loyalty. I look at the ratio of membership + package revenue to total revenue as a primary indicator of business quality. Below 20%, the business is transactional. Above 40%, it has genuine recurring characteristics.

Track churn carefully during diligence. Monthly membership churn rates above 8-10% indicate that customers aren't seeing sustained value, which undermines the recurring revenue thesis. Healthy IV therapy memberships should churn at 4-6% monthly — comparable to fitness memberships.

The Medical Director Arrangement

Every IV therapy business operates under a medical director — a physician (typically an MD or DO) who provides the standing orders that authorize nurses to administer IV treatments. This arrangement is not optional; it's a legal requirement in virtually every state. The structure of this relationship directly impacts valuation.

The cleanest arrangement is a contracted medical director providing oversight for a fixed monthly fee, typically $2,000-$5,000 per month depending on the state and scope. This contract should be documented, compliant with your state's corporate practice of medicine doctrine, and transferable to a new owner.

Red flags I look for: the medical director is a family member of the owner (creates transition risk), the medical director arrangement isn't documented in a formal agreement (legal exposure), or the medical director has no meaningful involvement in protocols and quality oversight (regulatory risk). If the medical director is the owner, you're really buying a medical practice, not a wellness business, and the valuation dynamics change entirely.

Mobile IV: The Margin Question

Many IV therapy businesses have added mobile services — house calls, hotel visits, event staffing, corporate wellness days. Mobile IV commands premium pricing ($250-$500+ per treatment) because of the convenience factor. Bachelorette parties, music festivals, corporate offices, and hotel concierge partnerships can generate meaningful revenue.

But mobile operations have different economics than a fixed location. Travel time between appointments, vehicle costs, portable equipment, and the logistics of sending a nurse to private residences all compress margins. A mobile IV treatment priced at $300 with 45 minutes of travel time has worse unit economics than a $200 treatment in a 6-chair infusion suite where the nurse is managing multiple concurrent patients.

I value mobile revenue at a slight discount to brick-and-mortar revenue unless the business has demonstrated scalable mobile operations — dedicated vehicles, route optimization, and a booking system that minimizes dead time. Mobile capability is a nice add-on, but it's rarely the core of a valuable IV therapy business.

The Regulatory Landscape: State-by-State Risk

This is the elephant in the room for IV therapy valuations. The regulatory framework for IV wellness infusions varies dramatically by state, and in many states it's still evolving. The core question is who can order and administer IV treatments outside of a traditional medical setting.

States with broad nurse practitioner scope of practice (like Arizona, Montana, and Colorado) allow NPs to practice independently, which simplifies the business model. States with restrictive physician supervision requirements (like California and Texas) require more structured medical director arrangements and create higher compliance costs.

Some states have begun specifically regulating IV hydration businesses. Florida, which has one of the densest IV therapy markets, requires businesses to register and comply with specific health department regulations. Other states are still catching up, which creates uncertainty that buyers factor into their offers.

I apply a regulatory risk discount of 10-15% to IV therapy valuations in states where the regulatory framework is ambiguous or actively tightening. A business operating in a state with clear, established regulations is worth more than an identical business in a state where the rules could change next legislative session.

Cash-Pay Model: Advantage and Limitation

Nearly all IV therapy revenue is cash-pay or credit card — insurance doesn't cover wellness infusions. This is simultaneously the best and most challenging aspect of the business model. On the positive side: no insurance billing complexity, no claim denials, no reimbursement rate pressure, and immediate payment at the time of service. The cash-pay model means clean revenue with minimal accounts receivable.

On the negative side: the business is entirely dependent on consumer discretionary spending. In an economic downturn, $250 vitamin drips are an easy expense to cut. This demand elasticity is a risk that buyers price into their offers. It's also why membership models are so critical — members are less likely to cancel during economic softness than walk-in customers are to reduce visit frequency.

The Bottom Line

IV therapy businesses are a legitimate and growing niche in the wellness economy, but valuations require careful analysis of unit economics, membership penetration, medical director arrangements, and state-specific regulatory risk. The best operators — those with strong recurring revenue, proper clinical infrastructure, and scalable systems — are building businesses worth 3-4x SDE that will attract buyer interest from both individual acquirers and multi-location wellness platforms. The operators running pop-up infusion lounges with no recurring revenue and informal medical oversight are building businesses that are difficult to sell at any multiple. Know which category you're in before you go to market.